Market Place
Sourcing Support
Abcellera To Release Q1 2026 Financial Results On May 11
01 Apr 2026 //
PHARMIWEB
Abcellera To Present At Investor Conferences In March-April 2026
11 Feb 2026 //
BUSINESSWIRE
Abcellera To Release 2025 Financial Results On Feb 24, 2026
22 Jan 2026 //
BUSINESSWIRE
Abcellera And Bruker Reach Global Settlement Of Patent Litigation
18 Dec 2025 //
PHARMIWEB
Abcellera Reports Q3 2025 Business Results
06 Nov 2025 //
BUSINESSWIRE
Abcellera To Release Q3 2025 Financial Results On November 6
29 Sep 2025 //
BUSINESSWIRE
AbCellera to Attend Investor Conferences in September
12 Aug 2025 //
BUSINESSWIRE
AbCellera Q2 2025 Results & Phase 1 Trial of ABCL635 Begins
07 Aug 2025 //
BUSINESSWIRE
AbCellera`s Q2 2025 Financial Results Due August 7, 2025
07 Jul 2025 //
BUSINESSWIRE
AbCellera Authorized by Health Canada for ABCL575 Phase 1 Trial
30 May 2025 //
BUSINESSWIRE
Court Upholds AbCellera Patent on Microfluidic Tech
12 May 2025 //
BUSINESSWIRE
AbCellera Reports Q1 2025 Business Results
08 May 2025 //
BUSINESSWIRE
AbCellera Shows Preclinical Efficacy of PSMA x CD3 T-Cell Engager
29 Apr 2025 //
BUSINESSWIRE
AbCellera to Attend Investor Conferences in May and June
08 Apr 2025 //
BUSINESSWIRE
AbCellera Reports Full Year 2024 Business Results
27 Feb 2025 //
BUSINESSWIRE
AbCellera to Participate at Upcoming Investor Conferences in March
11 Feb 2025 //
BUSINESSWIRE
AbCellera to Report Full Year 2024 Financial Results on Feb 27
21 Jan 2025 //
BUSINESSWIRE
AbCellera to Present at Investor Conferences in December & January
21 Nov 2024 //
BUSINESSWIRE
AbCellera Reports Q3 2024 Business Results
04 Nov 2024 //
BUSINESSWIRE
AbCellera To Report Q3 2024 Results On November 4
26 Sep 2024 //
BUSINESSWIRE
AbCellera to Present at Upcoming Investor Conferences in September
29 Aug 2024 //
BUSINESSWIRE
AbCellera Reports Q2 2024 Business Results
06 Aug 2024 //
BUSINESSWIRE
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
31 Jul 2024 //
BUSINESSWIRE
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
25 Jun 2024 //
BUSINESSWIRE
AbCellera: To Present At Goldman Sachs Healthcare Conference
28 May 2024 //
BUSINESSWIRE
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR
08 Apr 2024 //
BUSINESSWIRE
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
03 Apr 2024 //
BUSINESSWIRE
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
19 Mar 2024 //
BUSINESSWIRE
AbCellera to Collaborate with Biogen
11 Mar 2024 //
BUSINESSWIRE
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
05 Mar 2024 //
BUSINESSWIRE
AbCellera Announces Resignation of Board Member
23 Feb 2024 //
BUSINESSWIRE
AbCellera to Present at Upcoming Investor Conferences in March
22 Feb 2024 //
BUSINESSWIRE
AbCellera Reports Full Year 2023 Business Results
20 Feb 2024 //
BUSINESSWIRE
AbCellera to Report Full Year 2023 Financial Results on February 20, 2024
23 Jan 2024 //
BUSINESSWIRE
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference
20 Dec 2023 //
BUSINESSWIRE
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference
16 Nov 2023 //
BUSINESSWIRE
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
03 Nov 2023 //
BUSINESSWIRE
AbCellera Reports Q3 2023 Business Results
02 Nov 2023 //
BUSINESSWIRE
Prelude Therapeutics and AbCellera Enter Partnership
01 Nov 2023 //
GLOBENEWSWIRE
AbCellera to Present at the Jefferies London Healthcare Conference
31 Oct 2023 //
BUSINESSWIRE
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
11 Oct 2023 //
BUSINESSWIRE
AbCellera Announces Two T-Cell Engager Presentations at SITC 2023
27 Sep 2023 //
BUSINESSWIRE
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
20 Sep 2023 //
BUSINESSWIRE
AbCellera Reports Q2 2023 Business Results
03 Aug 2023 //
BUSINESSWIRE
AbCellera hopes to restart patent infringement lawsuits against Berkeley Lights
25 Jul 2023 //
ENDPTS
AbCellera Announces Board Has Denied Berkeley Lights’ Request for Rehearing
24 Jul 2023 //
BUSINESSWIRE
AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023
06 Jul 2023 //
BUSINESSWIRE
AbCellera to Present at the Goldman Sachs 44th Annual Healthcare Conference
29 May 2023 //
BUSINESSWIRE
AbCellera & Canada to invest $500M+ to boost antibody manufacturing and research
25 May 2023 //
ENPTS
AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
17 Apr 2023 //
BUSINESSWIRE
AbCellera to Present at Bloom Burton & Co. Healthcare Conference on April 25
11 Apr 2023 //
BUSINESSWIRE
AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023
06 Apr 2023 //
BUSINESSWIRE
AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies
22 Mar 2023 //
BUSINESSWIRE
AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
14 Mar 2023 //
BUSINESSWIRE
AbCellera to Present at Cowen 43rd Annual Health Care Conference on March 6
23 Feb 2023 //
BUSINESSWIRE
AbCellera Reports Full Year 2022 Business Results
22 Feb 2023 //
BUSINESSWIRE
AbCellera Reports Full Year 2022 Business Results
21 Feb 2023 //
BUSINESSWIRE
AbCellera to Present at SVB Biopharma Conference on February 15, 2023
01 Feb 2023 //
BUSINESSWIRE
AbCellera to Report Full Year 2022 Financial Results on February 21, 2023
24 Jan 2023 //
BUSINESSWIRE
AbCellera Announces U.S. Patent Trial Upholds Microfluidic Cell Culture Patent
19 Jan 2023 //
BUSINESSWIRE
